Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2012 1
2013 4
2015 1
2016 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Serova M, Tijeras-Raballand A, Dos Santos C, Martinet M, Neuzillet C, Lopez A, Mitchell DC, Bryan BA, Gapihan G, Janin A, Bousquet G, Riveiro ME, Bieche I, Faivre S, Raymond E, de Gramont A. Serova M, et al. Among authors: riveiro me. Oncotarget. 2016 Jun 21;7(25):38467-86. doi: 10.18632/oncotarget.9542. Oncotarget. 2016. PMID: 27509260 Free PMC article.
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Vázquez R, Licandro SA, Astorgues-Xerri L, Lettera E, Panini N, Romano M, Erba E, Ubezio P, Bello E, Libener R, Orecchia S, Grosso F, Riveiro ME, Cvitkovic E, Bekradda M, D'Incalci M, Frapolli R. Vázquez R, et al. Among authors: riveiro me. Int J Cancer. 2017 Jan 1;140(1):197-207. doi: 10.1002/ijc.30412. Epub 2016 Sep 19. Int J Cancer. 2017. PMID: 27594045 Free article.
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs.
Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F. Boi M, et al. Among authors: riveiro me. Clin Cancer Res. 2015 Apr 1;21(7):1628-38. doi: 10.1158/1078-0432.CCR-14-1561. Epub 2015 Jan 26. Clin Cancer Res. 2015. PMID: 25623213
Pharmacodynamic study of the 7,8-dihydroxy-4-methylcoumarin-induced selective cytotoxicity toward U-937 leukemic cells versus mature monocytes: cytoplasmic p21(Cip1/WAF1) as resistance factor.
Vázquez R, Riveiro ME, Mondillo C, Perazzo JC, Vermeulen M, Baldi A, Davio C, Shayo C. Vázquez R, et al. Among authors: riveiro me. Biochem Pharmacol. 2013 Jul 15;86(2):210-21. doi: 10.1016/j.bcp.2013.04.021. Epub 2013 May 9. Biochem Pharmacol. 2013. PMID: 23665351
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E. Serova M, et al. Among authors: riveiro me. Cancer Chemother Pharmacol. 2013 May;71(5):1297-307. doi: 10.1007/s00280-013-2129-6. Epub 2013 Mar 12. Cancer Chemother Pharmacol. 2013. PMID: 23479136
Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue.
Albert S, Hourseau M, Halimi C, Serova M, Descatoire V, Barry B, Couvelard A, Riveiro ME, Tijeras-Raballand A, de Gramont A, Raymond E, Faivre S. Albert S, et al. Among authors: riveiro me. Oral Oncol. 2012 Dec;48(12):1263-71. doi: 10.1016/j.oraloncology.2012.06.010. Epub 2012 Jul 7. Oral Oncol. 2012. PMID: 22776129
11 results